-
Featured
Novel Strategy Identified for Treating Osteoporosis
Cheng-Chia Tang, PhD, and Marc N. Wein, MD, PhD, of the Endocrine Unit, and colleagues demonstrated in a preclinical osteoporosis model that an oral drug, YKL-05–099, boosts bone formation and trabecular bone mass—and unlike current anabolic osteoporosis therapies, inhibits bone resorption.
-
After Denosumab Discontinuation, Alendronate Superior to Raloxifene at Maintaining BMD Gains
Massachusetts General Hospital researchers found that for postmenopausal women with osteoporosis who discontinue short-term denosumab treatment and are unable or unwilling to transition to a bisphosphonate, raloxifene may be a suitable alternative, although inferior in maintaining the gain in bone mineral density.
-
Mass General Researchers Develop New Oral Compound for Osteoporosis Prevention and Treatment
Massachusetts General Hospital researchers have identified a new compound that increased bone formation and bone mass when given orally to mice. Their findings may lead to a new, more convenient therapy for the prevention and treatment of osteoporosis.
-
Novel Mouse Model Allows Comparison of Candidate Parathyroid Hormone Ligand Analogs
Massachusetts General Hospital researchers have engineered a novel strain of mice that express the human parathyroid hormone 1 receptor (PTH1R) instead of the murine equivalent. These mice represent a potentially powerful new tool for developing PTH ligand analogs to treat bone and mineral ion metabolism diseases.
-
Exercise May Improve Bone Health in Youth With Type 1 Diabetes
Massachusetts General Hospital researchers conducted a study analyzing bone health in young individuals with and without type 1 diabetes. They found that individuals with diabetes who exercised less had worse markers of bone health compared to those without diabetes.
-
Osteoporosis Is Underrecognized, Undertreated Among Adults with Spinal Deformity Undergoing Long Fusion
In a retrospective study, spinal surgeons from Massachusetts General Hospital determined that one-third of adults scheduled for long thoracolumbar spinal fusions had osteoporosis before surgery, with two-thirds of those patients receiving no pharmacologic treatment.
Osteoporosis Contributors
-
Deborah M. Mitchell, MD
Pediatric Endocrinologist, Co-director, Pediatric Bone and Mineral Metabolism Disorders Clinic, Mass General for Children, Assistant Professor of Pediatrics, Harvard Medical School
Recent Article
Exercise May Improve Bone Health in Youth With Type 1 Diabetes -
Marc N. Wein, MD, PhD
Clinician-Researcher, Endocrine Unit, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Mass General Researchers Develop New Oral Compound for Osteoporosis Prevention and Treatment -
Stuart H. Hershman, MD
Director, Adult Spinal Deformity & Spinal Reconstruction, Site Director, Orthopaedic Spine Surgery Fellowship, Massachusetts General Hospital, Assistant Professor of Orthopaedic Surgery, Harvard Medical School
Recent Article
Vancomycin–Gentamicin Calcium Sulfate Beads May Predispose to Polymicrobial Infections After Adult Spinal Deformity Surgery
-
Thomas J. Gardella, PhD
Associate Investigator, Endocrine Unit, Mass General Research Institute, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
Novel Mouse Model Allows Comparison of Candidate Parathyroid Hormone Ligand Analogs
Endocrinology Division
The Endocrinology Division at Massachusetts General Hospital offers a comprehensive integrated program of clinical services for both primary and tertiary care of adults with endocrine disorders.